Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EQ101 · 1 trial · 4 indications
Number of participants with treatment-related adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE)
| Arm | Type | Description |
|---|---|---|
| EQ101 | EXPERIMENTAL | EQ101 weekly |
| Name | Type | Description |
|---|---|---|
| EQ101 | DRUG | EQ101, 2 mg/kg, once weekly dosing, for a total of 24 doses |
Key Inclusion Criteria: 1.Subjects have AA, meeting all of the following criteria: 1. Clinical diagnosis of AA with no other aetiology of hair loss ; 2. At least 35% scalp hair loss, as defined by a SALT score ≥ 35, at Screening and Baseline. Approximately 25% of subjects with 35% to \<50% scalp h...
EQ101 is an investigational small molecule being studied for the treatment of moderate to severe alopecia areata, including alopecia totalis and alopecia universalis. It is in Phase 2 clinical development and is not yet approved by regulatory authorities.
EQ101 is being developed by Equillium, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol EQ. The company is conducting clinical research to evaluate the safety and efficacy of this investigational therapy.
EQ101 is in Phase 2 clinical development. A Phase 2 study of the drug in adults with moderate to severe alopecia areata has been completed. The drug remains investigational and has not been approved for commercial use.
EQ101 has been studied in a Phase 2 clinical trial with the identifier NCT05589610, titled 'Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata.' This single-arm, uncontrolled study enrolled 36 participants in Australia and New Zealand and has been completed.
EQ101 is a distinct investigational small molecule developed by Equillium, Inc. No alternative names for this drug have been disclosed in the available clinical trial information. It is being evaluated specifically for alopecia areata and related conditions.